Clinical Trials Browser

OTHER × Carcinoma, Renal Cell × avelumab × Clear all

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Carcinoma, Renal Cell

NCT04068831 2024-12-27

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Phase 2 Completed

18 enrolled 9 charts

Carcinoma, Renal Cell

NCT03200587 2024-07-03

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Phase 1 Completed

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03341845 2018-05-21

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Phase 2 Unknown

Carcinoma, Renal Cell